Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference

Bess Frost¹, James B Rowe², Rufus O Akinyemi³, Jose F Abisambra⁴, Nicholas J Ashton^{5

6

7}, Matthias Brendel^{8

9

10

11}, Luc Buée¹², David Butler¹³, Maria C Carrillo¹⁴, Peter Chung¹⁵, Claire D Clelland^{16

17}, Sarah L DeVos¹⁸, Kristophe Diaz¹⁹, Rebecca M Edelmayer¹⁴, Fanny M Elahi^{20

21}, Ratnavalli Ellajosyula^{22

23}, Colin Ewen²⁴, Igor Camargo Fontana¹⁴, Marie-Christine Galas²⁵, Oskar Hansson²⁶, Günter Höglinger^{9

10

27}, Kanta Horie^{28

29}, Agustín Ibanez^{30

31

32}, Linde Jacobs³³, Mahmoud B Maina^{34

35}, Maura Malpetti^{36

37}, Eric McDade³⁸, Will McEwan³⁷, Laia Montoliu-Gaya³⁹, Catherine J Mummery⁴⁰, Miranda E Orr^{41

42}, Jonathan D Rohrer⁴⁰, Amy Rommel⁴³, Carlos Sastre⁴⁴, Tara L Spires-Jones^{45

46}, Boon Lead Tee^{17

31}, Tim J Viney⁴⁷, Jamie M Walker⁴⁸, Susanne Wegmann^{49

50}, Kristin Wildsmith²⁹, Ravi Yadav⁵¹, Simin Mahinrad¹⁴, Claire Sexton¹⁴

Affiliations

¹ Center for Alzheimer's Disease Research, Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, Rhode Island, USA.
² Department of Clinical Neurosciences, MRC Cognition and Brain Sciences Unit, and Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
³ Neuroscience and Ageing Research Unit, Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria.
⁴ McKnight Brain Institute, Brain Injury, Rehabilitation, and Neuroresilience Center, Center for Translational Research in Neurodegenerative Disease, Fixel Institute, Department of Neuroscience, University of Florida, Gainesville, Florida, USA.
⁵ Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.
⁶ Banner Alzheimer's Institute and University of Arizona, Phoenix, Arizona, USA.
⁷ Banner Sun Health Research Institute, Sun City, Arizona, USA.
⁸ Department of Nuclear Medicine, LMU University Hospital, Munich, Germany.
⁹ German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
¹⁰ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
¹¹ German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and Ludwig-Maximilians-Universität München (LMU), Heidelberg, Germany.
¹² Inserm, CHU-Lille, Lille Neuroscience & Cognition, University of Lille, Lille, France.
¹³ Neural Stem Cell Institute, Rensselaer, New York, USA.
¹⁴ Medical & Scientific Relations, Alzheimer's Association, Chicago, Illinois, USA.
¹⁵ Department of Physics and Astronomy, Department of Chemistry, and Alfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California, USA.
¹⁶ Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
¹⁷ Memory & Aging Center, University of California San Francisco, San Francisco, California, USA.
¹⁸ Cure.Bio, Boston, Massachusetts, USA.
¹⁹ CurePSP, Inc, New York, New York, USA.
²⁰ Departments of Neurology, Neuroscience, Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
²¹ James J. Peters Department of Veterans Affairs Medical Center, Bronx, New York, USA.
²² Cognitive Neurology Clinic, Manipal Hospital, and Annasawmy Mudaliar Hospital, Bengaluru, Karnataka, India.
²³ Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India.
²⁴ UCB Pharma, Slough, UK.
²⁵ Inserm, CHU Lille, CNRS, LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France.
²⁶ Lund University, Lund, Sweden.
²⁷ Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
²⁸ The Tracy Family SILQ Center & Department of Neurology, Washington University School of Medicine, St Louis, Missouri, USA.
²⁹ Eisai Inc., Nutley, New Jersey, USA.
³⁰ Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez (UAI), Peñalolén, Santiago, Chile.
³¹ Global Brain Health Institute (GBHI.org), University California San Francisco (UCSF), San Francisco, California, USA.
³² Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland.
³³ Cure MAPT FTD, Denver, Colorado, USA.
³⁴ Sussex Neuroscience, School of Life Sciences, University of Sussex, Falmer, UK.
³⁵ Biomedical Science Research and Training Centre, Yobe State University, Damaturu, Nigeria.
³⁶ Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.
³⁷ UK Dementia Research Institute, University of Cambridge, Cambridge, UK.
³⁸ Department of Neurology, Washington University, St. Louis, Missouri, USA.
³⁹ Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
⁴⁰ Dementia Research Centre, Institute of Neurology, University College London, London, UK.
⁴¹ Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
⁴² Salisbury VA Medical Center, Salisbury, North Carolina, USA.
⁴³ Rainwater Charitable Foundation, Fort Worth, Texas, USA.
⁴⁴ Global Medical Affairs, Ferrer, Barcelona, Spain.
⁴⁵ Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.
⁴⁶ UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.
⁴⁷ Department of Pharmacology, University of Oxford, Oxford, UK.
⁴⁸ Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
⁴⁹ German Center for Neurodegenerative Diseases, Berlin, Germany.
⁵⁰ Einstein Center for Neurosciences Berlin, Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁵¹ Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India.

PMID: 40437880
PMCID: PMC12120264
DOI: 10.1002/alz.70078

Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference

Bess Frost et al. Alzheimers Dement. 2025 May.

. 2025 May;21(5):e70078.

doi: 10.1002/alz.70078.

Authors

Affiliations

¹ Center for Alzheimer's Disease Research, Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, Rhode Island, USA.
² Department of Clinical Neurosciences, MRC Cognition and Brain Sciences Unit, and Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
³ Neuroscience and Ageing Research Unit, Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria.
⁴ McKnight Brain Institute, Brain Injury, Rehabilitation, and Neuroresilience Center, Center for Translational Research in Neurodegenerative Disease, Fixel Institute, Department of Neuroscience, University of Florida, Gainesville, Florida, USA.
⁵ Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.
⁶ Banner Alzheimer's Institute and University of Arizona, Phoenix, Arizona, USA.
⁷ Banner Sun Health Research Institute, Sun City, Arizona, USA.
⁸ Department of Nuclear Medicine, LMU University Hospital, Munich, Germany.
⁹ German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
¹⁰ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
¹¹ German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and Ludwig-Maximilians-Universität München (LMU), Heidelberg, Germany.
¹² Inserm, CHU-Lille, Lille Neuroscience & Cognition, University of Lille, Lille, France.
¹³ Neural Stem Cell Institute, Rensselaer, New York, USA.
¹⁴ Medical & Scientific Relations, Alzheimer's Association, Chicago, Illinois, USA.
¹⁵ Department of Physics and Astronomy, Department of Chemistry, and Alfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California, USA.
¹⁶ Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
¹⁷ Memory & Aging Center, University of California San Francisco, San Francisco, California, USA.
¹⁸ Cure.Bio, Boston, Massachusetts, USA.
¹⁹ CurePSP, Inc, New York, New York, USA.
²⁰ Departments of Neurology, Neuroscience, Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
²¹ James J. Peters Department of Veterans Affairs Medical Center, Bronx, New York, USA.
²² Cognitive Neurology Clinic, Manipal Hospital, and Annasawmy Mudaliar Hospital, Bengaluru, Karnataka, India.
²³ Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India.
²⁴ UCB Pharma, Slough, UK.
²⁵ Inserm, CHU Lille, CNRS, LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France.
²⁶ Lund University, Lund, Sweden.
²⁷ Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
²⁸ The Tracy Family SILQ Center & Department of Neurology, Washington University School of Medicine, St Louis, Missouri, USA.
²⁹ Eisai Inc., Nutley, New Jersey, USA.
³⁰ Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez (UAI), Peñalolén, Santiago, Chile.
³¹ Global Brain Health Institute (GBHI.org), University California San Francisco (UCSF), San Francisco, California, USA.
³² Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland.
³³ Cure MAPT FTD, Denver, Colorado, USA.
³⁴ Sussex Neuroscience, School of Life Sciences, University of Sussex, Falmer, UK.
³⁵ Biomedical Science Research and Training Centre, Yobe State University, Damaturu, Nigeria.
³⁶ Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.
³⁷ UK Dementia Research Institute, University of Cambridge, Cambridge, UK.
³⁸ Department of Neurology, Washington University, St. Louis, Missouri, USA.
³⁹ Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
⁴⁰ Dementia Research Centre, Institute of Neurology, University College London, London, UK.
⁴¹ Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
⁴² Salisbury VA Medical Center, Salisbury, North Carolina, USA.
⁴³ Rainwater Charitable Foundation, Fort Worth, Texas, USA.
⁴⁴ Global Medical Affairs, Ferrer, Barcelona, Spain.
⁴⁵ Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.
⁴⁶ UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.
⁴⁷ Department of Pharmacology, University of Oxford, Oxford, UK.
⁴⁸ Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
⁴⁹ German Center for Neurodegenerative Diseases, Berlin, Germany.
⁵⁰ Einstein Center for Neurosciences Berlin, Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁵¹ Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India.

PMID: 40437880
PMCID: PMC12120264
DOI: 10.1002/alz.70078

Abstract

Recent years have seen major advances in tau-associated brain disorders through interdisciplinary research spanning molecular biology, neuroimaging, clinical trials, and therapeutic development. The Tau2024 Global Conference, hosted by the Alzheimer's Association, CurePSP, and Rainwater Charitable Foundation, showcased these efforts by bringing together researchers and experts worldwide to discuss the latest advancements in tau research. The conference aimed to attract talent and funding to study tauopathies, particularly among early-career researchers, and to foster interdisciplinary alignment and collaboration around challenges in tau research. In this manuscript, we summarize proceedings of the Tau2024 Global Conference, covering a wide range of topics, including lived experiences of individuals with genetic forms of tauopathies, global perspectives on tauopathies, and molecular mechanisms, brain microenvironments, biomarker developments, clinical trials, and therapeutic approaches to tauopathies. Through international, collaborative efforts, innovative research, and a commitment to inclusivity, researchers worldwide have demonstrated transformative breakthroughs toward diagnosing, treating, and, ultimately, preventing tau-related diseases. HIGHLIGHTS: The Tau2024 Global Conference presented updates and advances in tau research. Blood-based biomarkers offer specificity and longitudinal monitoring capabilities. There are a range of targetable mechanisms in the cascade of pathogenesis. International collaboration is vital to address disparities in tauopathies.

Keywords: Alzheimer's disease; neurodegenerative disease; tau disorder; tau protein; tauopathies.

PubMed Disclaimer

Conflict of interest statement

M.C. Carrillo, I. Camargo Fontana, S. Mahinrad, and C. Sexton are full‐time employees of the Alzheimer's Association. N.J. Ashton, in the past 36 months, reports receiving consulting fees from Quanterix; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Alamar Biosciences, Biogen, Eli‐Lilly, Quanterix; patents (Application No.: PCT/US2024/037834 [WSGR Docket No. 58484‐709.601]), and served as Advisory Board for Biogen, TargetALS, and TauRx. L. Jacobs, in the past 36 months, reports receiving travel and lodging support for being the united keynote speaker by Alzheimer's Association and has a leadership or fiduciary role in Cure MAPT FTD. M. B. Maina, in the past 36 months, reports receiving consulting fees from Wellcome Trust; serving as a Member of Council, International Society to Advance Alzheimer's Research and Treatment; serving as Ambassador, ALBA Network (https://www.alba.network/); Governing of Society of Neuroscientists of Africa (SONA) and Yobe State Government–Special Adviser to The Governor. O. Hansson, in the past 36 months, reports receiving consulting fees from AC Immune, BioArctic, Biogen, Bristol Meyer Squibb, C2N Diagnostics, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens. M. Malpetti, in the past 36 months, reports receiving consulting fees from Astex Pharmaceuticals, Alzheimer's Association Travel Grant, Guarantors of Brain Travel Grant, ARUK East Network Travel Grant; and served as lead of the Inflammation Special DEMON Group, and the PET GENFI working group. R. Yadav, in the past 36 months, reports receiving royalties or licenses from Jaypee Publishers, New Delhi, received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from International PD and Movement Disorders Society, and served as Secretary of Movement Disorders Society of India. B. Frost, in the past 36 months, reports receiving consulting fees from MD Anderson Belfer Neurodegeneration Consortium, paid travel by Rainwater Foundation for attending Tau2024, Washington, D.C., paid travel by MD Anderson for attending MD Anderson Belfer Neurodegeneration Consortium Science Day, Houston, TX, and paid travel by NIH for attending CMND Study Section, Washington, D.C.; served as Co‐organizer of Tau2024 Conference, Scientific Advisory Board of CurePSP and Associate Editor of Progress in Neurobiology. L. Buee, in the past 36 months, reports receiving support from Rainwater Charitable Foundation for attending the Global Tau2024 Conference. D. Butler, in the past 36 months, reports support from the Rainwater Charitable Foundation and the Tau Consortium for attending meetings and/or travel and patents (Regenerative Research Foundation (2018). BI‐FUNCTIONAL ANTI‐TAU POLYPEPTIDES AND USE THEREOF. 27562‐0024WO1, Regenerative Research Foundation (2021) COMPOSITIONS AND METHODS FOR CONTROLLED PROTEIN DEGRADATION IN NEURODEGENERATIVE DISEASE (Pending)). C. D. Clelland, in the past 36 months, reports receiving support for attending Tau2024 and TCIM 2024. C. Ewen reports being an employee of UCB Ltd; receiving travel/hotel support for Tau2024 from the Rainwater Foundation; and stock or stock options in UCB Ltd. R. M. Edelmayer is a full‐time employee of the Alzheimer's Association, and the Alzheimer's Association provided support for the Tau2024 conference and writing of the manuscript, and Alzheimer's Association paid for her travel to Tau2024. K. Horie may receive income based on technology (METHODS TO DETECT MTBR TAU ISOFORMS AND USE THEREOF) (PCT/US2020/046224) licensed by Washington University to C2N Diagnostics. K. Horie may receive income based on technology (ANTI‐TAU MTBR ANTIBODIES AND METHODS TO DETECT ENDOGENOUSLY CLEAVED FRAGMENTS OF TAU AND USES THEREOF) (PCT/US2023/072738) licensed by Washington University to C2N Diagnostics. In addition, K. Horie reports the following patents: ANTI‐TAU MTBR ANTIBODIES AND METHODS TO DETECT ENDOGENOUSLY CLEAVED FRAGMENTS OF TAU AND USES THEREOF (PCT/US2023/072738), METHODS TO DETECT MTBR TAU ISOFORMS AND USE THEREOF (PCT/US2020/046224), and reports being an Eisai‐sponsored voluntary research associate professor at Washington University and has received a salary from Eisai. J. B. Rowe, in the past 36 months, reports royalties or licenses from Oxford University Press; receiving consulting fees from Asceneuron, Astex, Astronautx, ClinicalInk, CumulusNeuro, Cerevance Curasen, Eisai, ICG, Invicro, and Prevail; serving on the advisory board of Asceneuron and Dementia Mission; and being trustee of Guarantors of Brain, Darwin College, PSP Association. T. L. S. Jones, in the past 36 months, reports receiving consulting fees from AbbVie and Jay Therapeutics; receiving payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Sanofi; support for attending meetings and/or travel from Sanofi; and serving as president and trustee of British Neuroscience Association, Guarantors of Brain, trustee and editor of Brain Communications, Charity Scientific Advisor of Race Against Dementia, Scientific Advisory Board of Scottish Brain Sciences, and Scientific Advisory Board Cognition Therapeutics. C. J. Mummery, in the past 36 months, received consulting fees from Lilly as expert advisor in development of clinical program of siRNA J4T‐MCL‐0LAA; received honoraria for sponsored symposia: (a) Scientific symposium on novel DMTs in dementia; (b) educational symposium on DMTs from Lilly; received honoraria for sponsored symposium at ABN on implementation of leqembi in UK from Eisai; received paid registration fee and travel for UK National neurology conference (ABN) from Esiai, and paid registration and travel for AAIC as a Scientific Program Committee from Alzheimer's Association; and reports the following: Lilly – member of advisory board on donanemab Trailblazer; Novartis – member of advisory board on AD drug program steering committee; Roche/Genentech – member of advisory board for trontinemab, Eisai – member of advisory board on UK AUR for Leqembi, Chair data safety monitoring board Immunobrain, Biogen – advisor on program steering committee EMBARK/ENVISION aducanumab, Biogen – advisor on program steering committee and PI for phase II CELIA BIIB080, and Eisai – chair of AUR development UK committee for Leqembi. C. Sastré reports being Ferrer Employee. M. C. Galas, in the past 36 months, reports being an invited guest at the Tau2024 Global Conference. K. Diaz reports serving as Executive Director and CSO of CurePSP, Inc. K. Wildsmith, in the past 36 months, reports receiving support for attending meetings and/or travel from Eisai, Inc. and stock or stock options at Eisa, Inc. B. L. Tee, in the past 36 months, reports support for attending meetings and/or travel from NIA (R21AG068757, R01AG080469) and Alzheimer's Association (AACSFD‐22‐97214). F. M. Elahi, in the past 36 months, reports receiving consulting fees from Back Bay Life Science Advisors, Woolsey Pharmaceuticals, and Therini; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from academia only; support for attending meetings and/or travel from academia only; and serving on the cureCADASIL scientific advisory board, Eisai Alzheimer's disease advisory board, scientific advisory board member, Albert White Matter Research Institute, and scientific advisory board member and consultant, Cordance Medical. E. McDade, in the past 36 months, reports receiving consulting fees from AstraZeneca, Roche, Sanofi, and Merck; receiving payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Alzheimer Association, Projects in Knowledge (Kaplan)‐ CME, and Neurology Live–CME; receiving support for attending meetings and/or travel from Alzheimer's Association and Alzheimer's Foundation; patents planned, issued, or pending (T‐018562 – methods of treating based on site‐specific tau phosphorylation); participation on a data safety monitoring board or advisory board of Alector and Alnylam Pahrmaceuticals; having a leadership or fiduciary role paid or unpaid in Alzamend; and receiving equipment, materials, drugs, medical writing, gifts, or other services from Avid Radiopharmaceuticals, Cerveau, and LMI. G. Höglinger, in the past 36 months, reports receiving consulting fees from Abbvie, Alzprotect, Amylyx, Aprinoia, Asceneuron, Bayer, Bial, Biogen, Biohaven, Epidarex, Ferrer, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, Servier, Takeda, Teva, UCB; receiving payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Abbvie, Bayer, Bial, Biogen, Bristol Myers Squibb, Esteve, Kyowa Kirin, Pfizer, Roche, Teva, UCB, Zambon; receiving support for attending meetings and/or travel from Alzheimer's Association, CurePSP, Deutsche Gesellschaft für Neurologie, Deutsche Parkinson Gesellschaft, European Academy of Neurology and Movement Disorders Society; having patents planned, issued, or pending (Höglinger GU, Höllerhage M, Rösler T. Treatment of Synucleinopathies, United States Patent No.: US 10,918,628 B2, date of patent: February 16, 2021, and Höglinger GU, Höllerhage M, Rösler T. Treatment of Synucleinopathies. European Patent No.: EP 17 787 904.6‐1109 / 3 525 788.); participation on a Data Safety Monitoring Board or Advisory Board of Kainos Medicine; and having the following leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid: scientific advisory board, CurePSP, scientific advisory board, Parkinson Stiftung, scientific advisory board, Thiemann Stiftung, and clinical advisory board, DZNE. M. Brendel, in the past 36 months, reports receiving consulting fees from MICA and GE Healthcare; receiving payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from GE Healthcare, Miltnei, and Life Molecular Imaging; participation in a data safety monitoring board or advisory board of MIAC, and GE Healthcare; and having the following leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid: EANM Neuroimaging, and SNMMI BIC Board of Directors. S. L. DeVos, in the past 36 months, reports the following patens planned, issued, or pending: DeVos SL, Miller TM, Rigo F, Bennett CF. Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome. US20200032257A1. Published 01/2020. Patent Granted 10/2023, DeVos SL, Miller TM, Rigo F, Bennett CF. Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome. US10273474B2. Published 10/2015. Patent Granted 04/2019, DeVos SL, Barker S, Dennis MS, Estrada A, Kariolis M, Mahon C, Nilewski L, Park J, Shan L, Thayer MB, Tong R, Tran H, Wells R, Zuchero J. Oligonucleotide conjugates targeted to the TfR. WO2023279099A1. Published 01/2023. Patent Pending, DeVos SL, Ledeboer A, Zeitler B, Zhang S, Wegmann S, Hyman B. Tau modulators and methods and compositions for delivery thereof. US11504389B2. Published 06/2018. Patent Granted 11/2022, and DeVos SL, Ledeboer A, Zeitler B, Zhang S, Wegmann S, Hyman B. Tau modulators and methods and compositions for delivery thereof. US20230270774A1. Published 08/2023. Patent Pending. In addition, S. DeVos, in the past 36 months, reports having stock or stock options in Denali Therapeutics, Inc. J. D. Rohrer, in the past 36 months, reports receiving consulting fees from Alector, Prevail, Aviado Bio, Denali, Arkuda Therapeutics, and Takeda. J. F. Abisambra, in the past 36 months, reports receiving support for attending AAIC 2022. M. Orr, in the past 36 months, has received research support related to the present manuscript from Hevolution/AFAR, Cure Alzheimer's Fund, NIH grant 5R01AG068293‐05, the Alzheimer's Drug Discovery Foundation, and the Rainwater Charitable Foundation (these awards were granted to WFUHS, with Dr. M. E. Orr serving as the Principal Investigator). In addition, M. E. Orr received consulting fees from the Foundation for a Better World, received an honorarium for a keynote speech at a retreat at Case Western Reserve University, and an honorarium for a lecture from Washington University and Northwestern University. She received support for attending the following meetings and/or travel: AGE 51st Annual Meeting, AAIC 2023, 46th Annual Meeting of the Japanese Neuroscience Society, FBI Translations Seminar Series, CTAD 2023, ISCA 2023, GSA 2023, SfN 2023, Multidisciplinary Research in Gerontology Colloquium Series at USC, Progress in Neuroscience Seminar Series (PINS), AGBT 2024, ADPD 2024, ICM Seminar, Tau 2024, Palm Beach Science Series 2024, Japan Spatial Summit, ISMND 2024, Spatial Biology East Coast Summit, FrA2RE Meet and Greet Event, IMPACT‐AD Alumni Scholar Meeting, IRCND 2024, ADDF Pre‐AAIC Gathering, 2024 Neurobiology of Brain Disorders Gordon Research Conference, Case Western Annual Neurodegeneration Retreat and Goodes Prize Anniversary. She served as an unpaid advisor to Nanostring Technology and received free lab services from Nanostring Technology, Canopy Bio, and Averill Foundation. A. Rommel is an employee at Rainwater Charitable Foundation, which was a co‐funder of the Tau2024 conference. C. Sastre is a Ferrer employee. The remaining authors report no disclosures. Author disclosures are available in the Supporting Information.

References

1. Langerscheidt F, Wied T, Al Kabbani MA, Van Eimeren T, Wunderlich G, Zempel H. Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease‐like TAU pathology in primary and secondary tauopathies. J Neurol. 2024;271:2992‐3018. doi:10.1007/s00415-024-12314-3 - DOI - PMC - PubMed
1. Zhang Y, Wu K‐M, Yang L, Dong Q, Yu J‐T. Tauopathies: new perspectives and challenges. Mol Neurodegener. 2022;17:28. doi:10.1186/s13024-022-00533-z - DOI - PMC - PubMed
1. Ribeiro F, Teixeira‐Santos AC, Caramelli P, Leist AK. Prevalence of dementia in Latin America and Caribbean countries: systematic review and meta‐analyses exploring age, sex, rurality, and education as possible determinants. Ageing Res Rev. 2022;81:101703. doi:10.1016/j.arr.2022.101703 - DOI - PMC - PubMed
1. Mehta KM, Yeo GW. Systematic review of dementia prevalence and incidence in United States race/ethnic populations. Alzheimers Dement. 2017;13:72‐83. doi:10.1016/j.jalz.2016.06.2360 - DOI - PubMed
1. Ibanez A, Slachevsky A. Environmental‐genetic interactions in ageing and dementia across Latin America. Nat Rev Neurol. 2024;20:571‐572. doi:10.1038/s41582-024-00998-0 - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference

Affiliations

Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources